A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This study is being done for the following reasons:
The study has two parts. The purpose of the first part (Phase I) of the study is to find out
the highest dose of Afatinib that can be given safely with T-DM1.
The purpose of the second part of the study (Phase II) is to find out whether the dose of
Afatinib with T-DM1 determined in Phase I will keep breast cancer from getting worse for a
period of time.